GANX
Gain Therapeutics, Inc.
$1.82
-2.67%
2026-05-08
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Key Fundamentals
Forward P/E
-2.98
EPS (TTM)
$-0.61
ROE
-155.7%
Profit Margin
0.0%
Debt/Equity
3.94
Price/Book
4.22
Beta
0.15
Market Cap
$79.3M
Avg Volume (10D)
524K
Recent Breakout Signals
No recent breakout signals detected for GANX.
Recent Price Range (60 Days)
60D High
$3.07
60D Low
$1.67
Avg Volume
667K
Latest Close
$1.82
Get breakout alerts for GANX
Sign up for Breakout Scanner to receive daily notifications when GANX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Gain Therapeutics, Inc. (GANX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GANX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GANX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.